U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H25NO
Molecular Weight 271.3972
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOMETHORPHAN

SMILES

COC1=CC=C2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3C)C2=C1

InChI

InChIKey=MKXZASYAUGDDCJ-CGTJXYLNSA-N
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H25NO
Molecular Weight 271.3972
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26226106 | https://www.ncbi.nlm.nih.gov/pubmed/23628523 | https://www.ncbi.nlm.nih.gov/pubmed/24142584

Racemethorphan is racemic mixture of Dextromethorphan and Levomethorphan. Racemethorphan is listed under the Single Convention on Narcotic Drugs 1961 and is therefore listed in the United States as a Controlled Substance, specifically as a Narcotic in Schedule II. Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive. Dextromethorphan is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Levomethorphan is an opioid analgesic of the morphinan family that has never been marketed.

CNS Activity

Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/16634036

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Inhibition kinetics of monoclonal antibodies against cytochromes P450.
2002-06
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.
2002-06
Semi-automated liquid--liquid back-extraction in a 96-well format to decrease sample preparation time for the determination of dextromethorphan and dextrorphan in human plasma.
2002-05-25
Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial.
2002-05-11
The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6.
2002-05
Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials.
2002-05
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
2002-05
Modulation of human corticomotor excitability by somatosensory input.
2002-04-15
Analgesic effects of dextromethorphan and morphine in patients with chronic pain.
2002-04
Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
2002-04
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
2002-03-01
Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
2002-03-01
Is glutamate involved in transient lower esophageal sphincter relaxations?
2002-03
CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity.
2002-03
Selective suppression of late laryngeal adductor responses by N-methyl-D-aspartate receptor blockade in the cat.
2002-03
Glutamate-induced excitotoxicity in retina: neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers.
2002-02
Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.
2002-02
Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys.
2002-02
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
2002-01
Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
2002-01
Effect of ketamine, dextromethorphan, and MK-801 on cochlear dysfunction induced by transient ischemia.
2002-01
Dextromethorphan can produce false positive phencyclidine testing with HPLC.
2002-01
The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites.
2002
Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
2001-12-01
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
2001-12
CYP2D6 polymorphism in a Mexican American population.
2001-12
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin.
2001-12
Effects of dextromethorphan on nocturnal behavior and brain c-Fos expression in adolescent rats.
2001-11-09
Gas chromatographic method using nitrogen-phosphorus detection for the measurement of tramadol and its O-desmethyl metabolite in plasma and brain tissue of mice and rats.
2001-11-05
Important drugs for cough in advanced cancer.
2001-11
Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
2001-11
Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
2001-11
Co-administration of dextromethorphan during pregnancy and throughout lactation significantly decreases the adverse effects associated with chronic morphine administration in rat offspring.
2001-10-05
Abuse of Coricidin HBP cough & cold tablets: episodes recorded by a poison center.
2001-10-01
The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
2001-10
St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios.
2001-10
Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis.
2001-10
The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects.
2001-09-22
Dextromethorphan in pregnancy.
2001-09
Dextromethorphan increases tyrosine hydroxylase mRNA in the mesencephalon of adolescent rats.
2001-08-24
Dextromethorphan and dexmedetomidine: new agents for the control of perioperative pain.
2001-08
The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
2001-08
Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California.
2001-08
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001-08
Increasing bioanalytical throughput using pcSFC-MS/MS: 10 minutes per 96-well plate.
2001-07-01
Improved postoperative pain control in pediatric adenotonsillectomy with dextromethorphan.
2001-07
Dextromethorphan affects cocaine-mediated behavioral pattern in parallel with a long-lasting Fos-related antigen-immunoreactivity.
2001-06-29
Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers.
2001-05
Over-the-counter medications for acute cough in children and adults in ambulatory settings.
2001
Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl.
2001
Patents

Sample Use Guides

Levomethorphan (dissolved in a mixed solution of 5% Emulphor™ EL-620/5% ethanol/90% isotonic sodium chloride solution, 2.5 mg/mL, rat 4–6) was administered to male DA pigmented rats, which were 5 weeks old and around 90 g mean weight. The drugs were given once daily at 5 mg/kg by intraperitoneal injection for ten successive days.
Route of Administration: Intraperitoneal
Liver microsomes from individual male dark agouti (DA) rats (n=4, 6 weeks old, around 125 g mean weight) were prepared by ultracentrifugation. For the in vitro experiments with rat and human liver microsomes, the reaction mixture consisted of 0.1 M potassium phosphate buffer (pH 7.4) with an NADPH generating system (1.3 mM NADP, 3.3 mM G-6-P, 0.4 U/ mL G-6-PDH, 3.3 mM MgCl2), 50 μM substrate (dextromethorphan or levomethorphan), and 0.5 mg protein/mL microsomes (rat or human liver microsomes) in a final volume of 200 μL. Dextromethorphan and levomethorphan were dissolved in methanol, and the final concentration of the organic solvent was 0.1%. The incubation was started by adding the microsomal fraction and then continued for 0, 5, 10, or 20 min. The reaction was terminated by adding an equal volume of a mixed organic solution of 50% acetonitrile and 50% methanol, including 10 μM levallorphan (IS), and vigorous shaking.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:19:11 GMT 2025
Edited
by admin
on Mon Mar 31 18:19:11 GMT 2025
Record UNII
7ZZ22K9QE6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOMETHORPHAN
INN   MI  
INN  
Official Name English
IDS-NL-004
Preferred Name English
LEVOMETHORPHAN [MI]
Common Name English
levomethorphan [INN]
Common Name English
L-METHORPHAN
Common Name English
LEVOMETHORPHAN SOLUTION [USP-RS]
Common Name English
(-)-3-METHOXY-N-METHYLMORPHINAN
Systematic Name English
2H-10,4A-IMINOETHANOPHENANTHRENE, 1,3,4,9,10,10A-HEXAHYDRO-6-METHOXY-11-METHYL-
Systematic Name English
IDS-NL-005
Code English
MORPHINAN, 3-METHOXY-17-METHYL-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
DEA NO. 9210
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
Code System Code Type Description
EVMPD
SUB08478MIG
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
WIKIPEDIA
LEVOMETHORPHAN
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
INN
148
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
CHEBI
146176
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
NCI_THESAURUS
C83875
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-751-7
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID20872403
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
FDA UNII
7ZZ22K9QE6
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
ChEMBL
CHEMBL1908323
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
MERCK INDEX
m6790
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY Merck Index
SMS_ID
100000082278
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
CAS
125-70-2
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
PUBCHEM
5362449
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
RS_ITEM_NUM
1362359
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
Related Record Type Details
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY